Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer (MITO16MANGO2b)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01802749|
Recruitment Status : Active, not recruiting
First Posted : March 1, 2013
Last Update Posted : March 24, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Bevacizumab has been found to prolong progression free survival in first line, and more recently, in second line treatment for platinum sensitive ovarian cancer patients who had not received prior treatment with bevacizumab.
Recently reported data suggest that patients with colon cancer who receive bevacizumab in more than one line of therapy (beyond progression) have better results. In ovarian cancer, the role of bevacizumab administered in both first and second-line therapies needs to be defined.
This study aims to evaluate whether administering bevacizumab in combination with chemotherapy in second-line therapy to patients with recurrent ovarian cancer who have received first-line bevacizumab will be more effective than chemotherapy alone.
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Ovarian Cancer||Drug: Bevacizumab Drug: Paclitaxel Drug: Carboplatin Drug: pegylated liposomal doxorubicin Drug: Gemcitabine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||406 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line|
|Study Start Date :||November 2013|
|Estimated Primary Completion Date :||December 2023|
|Estimated Study Completion Date :||December 2023|
Active Comparator: chemotherapy
Combination chemotherapy with ONE of the following regimens:
Drug: pegylated liposomal doxorubicin
Other Name: Caelyx
Experimental: Chemotherapy and bevacizumab
Combination chemotherapy AND bevacizumab with ONE of the following regimens:
Patients whose disease has not progressed after the initial six cycles of combination treatment will continue bevacizumab, at 15 mg/kg every 3 weeks until disease progression,unacceptable toxicity or patient withdrawn.
Other Name: Avastin
Drug: pegylated liposomal doxorubicin
Other Name: Caelyx
- progression free survival [ Time Frame: 12 months ]assessed by local Investigator
- overall survival [ Time Frame: 12 months ]
- number of complete or partial responses [ Time Frame: 6 months ]according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- worst grade toxicity per patient [ Time Frame: evaluated every 3 weeks up to 12 months ]according to Common Toxicity Criteria for Adverse Events v. 4.03
- number of patients taking oral antidiabetic therapy [ Time Frame: at baseline ]
- number of patients taking antithrombotic therapy [ Time Frame: at baseline ]
- progression free survival [ Time Frame: 12 months ]as measured by independent central review
- predictive clinical factors for efficacy of bevacizumab [ Time Frame: 12 months ]
- correlation of baseline plasma biomarker expression and clinical outcome [ Time Frame: 12 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
- Female patients ≥18 years of age.
- Patients with histologically confirmed epithelial ovarian or fallopian tube carcinoma or primary peritoneal carcinoma, including mixed Mullerian Tumours
- Recurrence or progression at least 6 months after the last chemotherapy cycle of a first line carboplatin + paclitaxel chemotherapy including bevacizumab (recurrence or progression might occur either during or after bevacizumab as maintenance)
- Patients can be included if they have a RECIST progression, with either measurable or non-measurable disease
- ECOG (Eastern Cooperative Oncology Group Performance) Status of 0-2.
- Life expectancy of at least 12 weeks.
- Signed informed consent obtained prior to initiation of any study-specific procedures and treatment as confirmation of the patient's awareness and willingness to comply with the study requirements including blood samples for molecular analyses.
- Availability of tumour samples for molecular analyses from primary surgery (mandatory) and secondary surgery (when available)
- Ovarian tumours with low malignant potential (i.e. borderline tumours)
History or evidence of synchronous primary endometrial carcinoma, unless all of the following criteria related to the endometrial carcinoma are met:
- stage ≤Ia
- no more than superficial myometrial invasion
- no lymphovascular invasion
- not poorly differentiated (grade 3 or papillary serous or clear cell carcinoma).
- Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
Prior current or planned treatment:
- More than one previous chemotherapy line
- Previous therapy with other anti-angiogenetic agents different from bevacizumab.
- Any prior radiotherapy to the pelvis or abdomen.
- Surgery (including open biopsy) within 4 weeks prior to the first bevacizumab dose.Current or recent (within 10 days prior to the first study drug dose) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes (except for line patency, in which case international normalized ratio [INR] must be maintained below 1.5). Post operative prophylaxis with low molecular weight heparin sc is allowed.
- Current or recent (within 30 days of first study dosing) treatment with any other investigational drug.
- Inadequate bone marrow function: ANC (absolute neutrophil count): <1500/mm3, or platelet count <100,000/mm3 or Haemoglobin <9 g/dl. Patients may be transfused to maintain haemoglobin values ≥9 g/dl.
Inadequate coagulation parameters:
- activated partial thromboplastin time (APTT) >1.5 x upper limit of normal (ULN) or
- INR (international normalized ratio) >1.5
Inadequate liver function, defined as:
- serum (total) bilirubin >1.5 x ULN for the institution
- AST/SGOT or ALT/SGPT > 2.5 x ULN.
Inadequate renal function, defined as:
- serum creatinine >2.0 mg/dl or >177 micromol/l
- urine dipstick for proteinuria >2+. Patients with ≥ 1+ proteinuria at baseline dipstick analysis should undergo a 24-hour urine collection and must demonstrate ≤1g of protein in their 24-hour urine collection.
Prior or concomitant conditions or procedures:
- History or evidence of brain metastases or spinal cord compression.
- Pregnant or lactating females.
- History or evidence of thrombotic or haemorrhagic disorders; including cerebrovascular accident (CVA) / stroke or transient ischemic attack (TIA) or sub-arachnoid haemorrhage within ≤6 months prior to the first study treatment).
- Uncontrolled hypertension (sustained systolic >150 mm Hg and/or diastolic >100 mm Hg despite antihypertensive therapy) or clinically significant (i.e. active) cardiovascular disease, including:
- myocardial infarction or unstable angina within ≤6 months prior to the first study treatment
- New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF)
- serious cardiac arrhythmia requiring medication (with the exception of atrial fibrillation or paroxysmal supraventricular tachycardia)
- peripheral vascular disease ≥grade 3 (i.e. symptomatic and interfering with activities of daily living requiring repair or revision).
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess, or with signs of impending bowel obstruction within 6 months prior to the first study treatment.
- Non-healing wound, ulcer or bone fracture. Patients with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection are eligible but require three weekly wound examinations.
- Evidence of any other medical conditions (such as psychiatric illness, peptic ulcer, etc.), physical examination or laboratory findings that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01802749
|Principal Investigator:||Sandro Pignata, M.D., Ph.D.||National Cancer Institute, Naples|
|Principal Investigator:||Nicoletta Colombo, M.D.||European Institute of Oncology|
|Principal Investigator:||Francesco Perrone, M.D., Ph.D.||National Cancer Institute, Naples|
|Principal Investigator:||Gennaro Daniele, M.D., Ph.D.||National Cancer Institute, Naples|
|Principal Investigator:||Roldano Fossati, M.D.||Mario Negri Institute|
|Principal Investigator:||Ciro Gallo, M.D.||University of Campania "Luigi Vanvitelli"|
|Principal Investigator:||Irene Floriani, Ph.D.||Mario Negri Institute|
|Responsible Party:||National Cancer Institute, Naples|
|Other Study ID Numbers:||
2012-004362-17 ( EudraCT Number )
ENGOT-ov 17 ( Other Identifier: ENGOT )
|First Posted:||March 1, 2013 Key Record Dates|
|Last Update Posted:||March 24, 2023|
|Last Verified:||March 2023|
first line bevacizumab
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Genital Neoplasms, Female
Endocrine System Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Immune System Diseases
Antineoplastic Agents, Phytogenic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological